These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28290122)

  • 1. Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs.
    Usmani OS; Molimard M; Gaur V; Gogtay J; Singh GJP; Malhotra G; Derom E
    Clin Pharmacokinet; 2017 Oct; 56(10):1139-1154. PubMed ID: 28290122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
    Weber B; Hochhaus G
    AAPS J; 2015 Jul; 17(4):999-1010. PubMed ID: 25933600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.
    Hendeles L; Daley-Yates PT; Hermann R; De Backer J; Dissanayake S; Horhota ST
    AAPS J; 2015 May; 17(3):758-68. PubMed ID: 25716149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol.
    Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L
    J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
    Lähelmä S; Sairanen U; Haikarainen J; Korhonen J; Vahteristo M; Fuhr R; Kirjavainen M
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report.
    O'Connor D; Adams WP; Chen ML; Daley-Yates P; Davis J; Derendorf H; Ducharme MP; Fuglsang A; Herrle M; Hochhaus G; Holmes SM; Lee SL; Li BV; Lyapustina S; Newman S; Oliver M; Patterson B; Peart J; Poochikian G; Roy P; Shah T; Singh GJ; Sharp SS
    J Aerosol Med Pulm Drug Deliv; 2011 Jun; 24(3):119-35. PubMed ID: 21453049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
    Agertoft L; Pedersen S
    Am J Respir Crit Care Med; 2003 Oct; 168(7):779-82. PubMed ID: 12893646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.
    Soulele K; Macheras P; Karalis V
    Biopharm Drug Dispos; 2017 Oct; 38(7):407-419. PubMed ID: 28374512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products.
    Daley-Yates PT; Parkins DA; Thomas MJ; Gillett B; House KW; Ortega HG
    Clin Ther; 2009 Feb; 31(2):370-85. PubMed ID: 19302910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic optimisation of asthma treatment.
    Taburet AM; Schmit B
    Clin Pharmacokinet; 1994 May; 26(5):396-418. PubMed ID: 7914480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Markham A; Jarvis B
    Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
    Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
    Reynolds NA; Lyseng-Williamson KA; Wiseman LR
    Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
    Adams WP; Ahrens RC; Chen ML; Christopher D; Chowdhury BA; Conner DP; Dalby R; Fitzgerald K; Hendeles L; Hickey AJ; Hochhaus G; Laube BL; Lucas P; Lee SL; Lyapustina S; Li B; O'Connor D; Parikh N; Parkins DA; Peri P; Pitcairn GR; Riebe M; Roy P; Shah T; Singh GJ; Sharp SS; Suman JD; Weda M; Woodcock J; Yu L
    J Aerosol Med Pulm Drug Deliv; 2010 Feb; 23(1):1-29. PubMed ID: 20131983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD.
    Fuglsang A
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):243-7. PubMed ID: 22857274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.
    Rebello J; Brashier B; Shukla S
    Daru; 2022 Jun; 30(1):229-243. PubMed ID: 35094370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The recent paper by Daley-Yates et al.
    Fuglsang A; Thyroff-Friesinger U; Gross J
    Clin Ther; 2009 Aug; 31(8):1881-2; author reply 1882-4. PubMed ID: 19808147
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.